Product quality questions raised during a biosimilar application mid-assessment cycle meeting appear to be a strong signal that the US Food and Drug Administration may issue a complete response letter.
The first-cycle approval rate for biosimilar applications when a product quality issue was discussed during a mid- or late-assessment cycle...






